CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $32,817 | -19.3% | 723 | -0.1% | 0.00% | – |
Q2 2023 | $40,646 | +24.5% | 724 | +0.3% | 0.00% | – |
Q1 2023 | $32,657 | +8.6% | 722 | -2.4% | 0.00% | – |
Q4 2022 | $30,081 | -38.6% | 740 | -0.4% | 0.00% | -100.0% |
Q3 2022 | $49,000 | +8.9% | 743 | +0.8% | 0.00% | 0.0% |
Q2 2022 | $45,000 | +18.4% | 737 | +21.0% | 0.00% | – |
Q1 2022 | $38,000 | +375.0% | 609 | +443.8% | 0.00% | – |
Q4 2021 | $8,000 | -38.5% | 112 | 0.0% | 0.00% | – |
Q3 2021 | $13,000 | 0.0% | 112 | +40.0% | 0.00% | – |
Q2 2021 | $13,000 | +30.0% | 80 | 0.0% | 0.00% | – |
Q1 2021 | $10,000 | -16.7% | 80 | 0.0% | 0.00% | – |
Q4 2020 | $12,000 | – | 80 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |